NEWPORT BEACH, CA / ACCESSWIRE / February 22, 2017 / Gregory DiRienzo, CEO of New Life Cancer Centers (www.newlifecancercenters.com), announces its "first-of-its-kind" introduction within North America, SonataPlus, and a personalized, minimally invasive intratumoral immuno-chemo protocol for treatment of the most advanced solid cancer tumors."
Chinese clinical researcher and oncologist, Baofa Yu, has administered minimally invasive intratumoral immuno-chemo therapy for over 20 years to thousands of patients at Dr. Yu's cancer hospitals located outside Beijing, China, which first became of interest to Dr. Yu while undergoing studies in alternative drug delivery systems in the late 1990's at the University of California, San Diego, and later Salk Institute of Biological Research, La Jolla, CA.
A clinical study published in the December 2015 issue of "Journal of Liver Research, Disorders and Therapy" revealed that Dr Yu's protocol (which includes a hapten component), administered before standard surgery and/or radiation treatment, was shown to shrink and possibly destroy pancreatic tumor(s) within weeks before commencing of any treatment for late stage pancreatic cancers.
The concept of intratumoral drug delivery has been known for years, with some showing clinical feasibility via significant reduction in toxicity and tumor growth but not in pancreatic cancer. Pancreatic cancer is in a crucial organ surrounded by vital tissues and organs, such as the duodenum, gallbladder, portal vein, and aorta. Tumor invasion of these organs by pancreatic cancer is most common and generally leads to unresectability.
According to Dr. Yu, significant results presented within the study could lead to fewer patients requiring surgically invasive tumor removal. Moreover, by administering slow released chemo drugs together with hapten directly into the tumor, it was shown that potential ongoing immunology for deterring and/or hampering of pancreatic cancer metastasis. In this study, a combination of medicines for treatment of solid tumors was explored with dosages based upon tumor-size and inclusion of patient-specific autologous tumor antigens to induce a self-vaccination tumor-specific response.
The study described the results of 86 patients diagnosed with late stage pancreatic cancer whose treatments failed standard therapy, then treated with minimally invasive intratumoral immuno-chemo therapy. The protocol relies primarily on an intratumoral injection procedure that combines an approved oxidant, select chemo medicines and hapten based immune enhancer to achieve full coagulation and necrotic efficacy within the particular tumor mass. It was observed that coagulation within the tumor inhibited overall blood flow and encapsulation of the injected chemo's at higher concentrations and for significantly more days than observed in conventional drug delivery protocols.